Analysis of the key themes driving M&A activity reveals that smart hospitals accounted for 16 pharmaceutical deals announced in Q1 2024, worth a total value of $101.4m. The $95m acquisition of C2i Genomics by Veracyte was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, smart hospitals-related deal activity decreased by 94% in Q1 2024 compared with the previous quarter’s total of $1.6bn and rose by 4% as compared to Q1 2023. Related deal volume decreased by 16% in Q1 2024 versus the previous quarter.
The top-ranked financial advisors supporting these M&A deals in Q1 2024 were KPMG International Coop; Morgan Stanley; Perella Weinberg Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q1 2024 were Cooley; Debevoise & Plimpton; Fenwick & West with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.